Covalent Drug Discovery and Development Summit on October 20-22, 2026 in Boston, United States

Covalent drug discovery has entered a defining new phase where scientific validation is no longer the primary barrier; successful clinical translation now takes center stage.

Once limited by concerns around off-target toxicity, covalent approaches are now unlocking undruggable targets and expanding beyond oncology into new therapeutic areas. As next-generation warheads, chemoproteomics, and AI-driven design accelerate innovation, the key challenge is clear: how to translate covalent candidates into safe, effective clinical therapies.

The 4th Covalent Drug Discovery and Development Summit is the only industry forum dedicated to advancing covalent therapeutics end-to-end, from discovery through to IND and early clinical development.

Uniting experts from Bristol Myers Squibb, Novartis, Pfizer, Biogen, Nexo Therapeutics, and Frontier Medicines, this summit goes beyond high-level discussion to deliver data-driven case studies, translational strategies, and real clinical insights.

Join 80+ covalent leaders to:

De-risk your pipeline with early clinical and translational learnings

Overcome selectivity, safety, and PK/PD challenges

Gain candid insights not found in publications

As more covalent drugs enter the clinic, now is the time to turn promise into proof.

URLs:
Tickets: https://go.evvnt.com/3686853-2?pid=10008
Brochure: https://go.evvnt.com/3686853-3?pid=10008

Time: 8:00 AM - 3:10 PM

Venue Details: Hampton Inn Boston Seaport District, 670 Summer Street, Boston, Massachusetts, 02210, United States

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development

Prices:

Drug Developer Pricing - Full Access Pass: Conference + Workshop Day: USD 4397.00,

Drug Developer Pricing - Conference Only: USD 3099.00,

Academic Pricing - Full Access Pass: Conference + Workshop Day: USD 3797.00,

Academic Pricing - Conference Only: USD 2699.00,

Service Provider Pricing - Full Access Pass: Conference + Workshop Day: USD 5297.00,

Service Provider Pricing - Conference Only: USD 3799.00

Speakers: Doug Johnson, Senior Director, Biogen, Jack Sloane, Senior Principal Scientist, Bristol Myers Squibb, Julian Dopstadt, Director, Eli Lilly, Jeffrey McKenna, Director, Novartis, Jaimeen Majmudar, Head Research Fellow, Chemical Biology, Pfizer, Claire Metrick, Senior Scientist, Structural Biology, Takeda Pharmaceutical, Weixue Wang, Senior Director, Antares Therapeutics, Chris Haggard, Co-Founder and Chief Technical Officer, Axiom Therapeutics, Petr Jansa, Vice President, Head of Chemistry, BridGene Biosciences Inc., Na Li, Vice President, DMPK, Cellarity, Antony Burton, Associate Director, Chemical Biology and Proteomics, Dunad Therapeutics, Antony Burton, Associate Director, Chemical Biology and Proteomics, Dunad Therapeutics, Jacob Stuckey, Vice President, Biochemistry and Chemical Biology, Flare Therapeutics, Jay Duffner, Director and Head of Discovery Biology, Frontier Medicines, Rhamy Zeid, Chief Scientific Officer, Nexo Therapeutics, Alex Federation, Co-Founder and Chief Executive Officer, Talus Bio, Mu-Sen Liu, Head Biochemist and Senior Scientist, Tango Therapeutics, Sara Buhrlage, Associate Professor, Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Jianwei (John) Che, Core Director, Dana-Farber Cancer Institute, Stephan Hacker, Assistant Professor, Leiden University, Ken Hsu, Associate Professor, The University of Texas at Austin